April 12th 2024
Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.
April 4th 2024
Petros Grivas, MD, PhD, discusses potential future directions for adjuvant therapies in patients with resected renal cell carcinoma.
February 8th 2024
Petros Grivas, MD, PhD, discusses 2023 updates regarding the treatment of patients with metastatic/unresectable urothelial carcinoma.
January 10th 2024
Petros Grivas, MD, PhD, discusses outcomes associated with the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma.
May 18th 2023
Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.
A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.
May 11th 2023
Shared insight on clinical trial data behind the intensification of maintenance immunotherapy in patients with metastatic urothelial carcinoma.
Centering discussion on several key clinical trials, expert panelists reflect on data behind maintenance avelumab in metastatic urothelial carcinoma.
May 4th 2023
A panel of four key opinion leaders discuss the role of maintenance therapy in metastatic urothelial carcinoma and how its use has impacted the treatment landscape.
A brief review of the appropriate number of chemotherapy cycles to utilize in the setting of metastatic urothelial carcinoma.
April 27th 2023
Switching their focus to the metastatic urothelial carcinoma treatment landscape, panelists identify cornerstone frontline treatment options.
A comprehensive review of novel treatment strategies in MIBC, including perioperative therapy, and respective ongoing clinical trials.
April 20th 2023
Expert panelists reflect on the molecular subtyping of patients to predict response to neoadjuvant therapy in Bladder BRIDGister.
Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.
April 13th 2023
Focused discussion on the RETAIN BLADDER study, which explored the option to avoid cystectomy in patients with good response to systemic therapy.
Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.
April 6th 2023
Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.
Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.
March 30th 2023
Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.
A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.